DREAMM-10
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Near Add Your Location
Sorting 18 by
Infirmary Cancer Care
Mobile, AL
- Accepting patients
Community Clinical Trials
Houston, TX
- Accepting patients
Lifespan Rhode Island Hospital
Providence, RI
- Not yet accepting
OhioHealth Riverside Methodist Hospital
Columbus, OH
- Not yet accepting
- Not yet accepting
St. Vincent Frontier Cancer Center
Billings, MT
- Not yet accepting
MaineHealth Maine Medical Center
Scarborough, ME
- Not yet accepting
- Not yet accepting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack Meridian Health
Hackensack, NJ
- Not yet accepting
Stony Brook University Hospital
Stony Brook, NY
- Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.